Récepteur Trk
Les inhibiteurs des récepteurs Trk ciblent les kinases des récepteurs de la tropomyosine (Trk), une famille de récepteurs à activité tyrosine kinase qui jouent un rôle important dans le développement et la fonction du système nerveux. Les récepteurs Trk sont impliqués dans la signalisation des neurotrophines, essentielle à la survie, à la différenciation et à la croissance des neurones. La dérégulation de la signalisation Trk est associée à des troubles neurologiques et à certains cancers. Chez CymitQuimica, nous proposons des inhibiteurs de récepteurs Trk pour soutenir vos recherches en neurobiologie, oncologie et maladies neurodégénératives.
Produits appartenant à la catégorie "Récepteur Trk"
Trier par
LM22A-4
CAS :LM22A-4: BDNF mimetic, TrkB agonist, IC50=47 nM (fluorescence anisotropy).Formule :C15H21N3O6Degré de pureté :99.56%Couleur et forme :SolidMasse moléculaire :339.34Tyrphostin AG 879
CAS :Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.Formule :C18H24N2OSDegré de pureté :99.05%Couleur et forme :SolidMasse moléculaire :316.46PF-06733804
CAS :PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.Formule :C20H19F5N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :474.38CG 428
CAS :CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.Formule :C43H43FN10O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :814.86Ref: TM-T41224
1mg170,00€5mg423,00€10mg623,00€25mg938,00€50mg1.311,00€100mg1.786,00€500mg3.591,00€1mL*10mM (DMSO)437,00€Paltimatrectinib
CAS :Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.Formule :C20H15F5N6Degré de pureté :99.96%Couleur et forme :SolidMasse moléculaire :434.37Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Degré de pureté :98%Couleur et forme :Odour SolidLarotrectinib sulfate
CAS :Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).Formule :C21H22F2N6O2·H2O4SDegré de pureté :98.62% - 99.69%Couleur et forme :SolidMasse moléculaire :526.51Ref: TM-T6880
2mg39,00€5mg57,00€10mg93,00€25mg131,00€50mg163,00€100mg274,00€500mg658,00€1mL*10mM (DMSO)66,00€GW 441756
CAS :GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.Formule :C17H13N3ODegré de pureté :97.73% - 99.8%Couleur et forme :SolidMasse moléculaire :275.3TrkA-IN-8
CAS :TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.Formule :C20H16N4Couleur et forme :SolidMasse moléculaire :312.368Amitriptyline hydrochloride
CAS :Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptiveFormule :C20H24ClNDegré de pureté :97% - 99.94%Couleur et forme :Crystals White To Off-White PowderMasse moléculaire :313.86Repotrectinib
CAS :Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.Formule :C18H18FN5O2Degré de pureté :100% - 99.92%Couleur et forme :SolidMasse moléculaire :355.37Ref: TM-T4071
1mg49,00€2mg70,00€5mg96,00€10mg169,00€25mg296,00€50mg474,00€100mg688,00€1mL*10mM (DMSO)100,00€DS-1205
CAS :DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formule :C41H42FN5O7Degré de pureté :99.28%Couleur et forme :SolidMasse moléculaire :735.8TRK-IN-23
CAS :TRK-IN-23 (compound 24b) is a potent, orally active inhibitor of TRK with IC50s of 0.5 nM for TRKA, 9 nM for TRKC, 14 nM for TRKA G595R, 4.4 nM for TRKA F589L,Formule :C20H17FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :364.37CE-245677
CAS :CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.Formule :C24H22Cl2N6O3Degré de pureté :98.99% - 99.23%Couleur et forme :SolidMasse moléculaire :513.38Ref: TM-T14921
1mg62,00€2mg87,00€5mg119,00€10mg187,00€25mg313,00€50mg432,00€100mg638,00€1mL*10mM (DMSO)136,00€Anti-TrkB/NTRK2 Antibody
Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.Couleur et forme :Odour LiquidHS-345
CAS :HS-345, a TrkA/Akt inhibitor, exhibits potent anti-pancreatic cancer properties. This compound inhibits the growth and proliferation of pancreatic cancer cells by blocking the TrkA/Akt signaling pathway and induces cell apoptosis (Apoptosis). Additionally, HS-345 inhibits angiogenesis by reducing the expression of HIF-1α and VEGF. It holds promise for use in pancreatic cancer research.Formule :C19H18N6O2SCouleur et forme :SolidMasse moléculaire :394.45BMS-754807
CAS :BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Formule :C23H24FN9ODegré de pureté :98.86%Couleur et forme :SolidMasse moléculaire :461.49Ref: TM-T2349
1mg49,00€2mg70,00€5mg96,00€10mg166,00€25mg328,00€50mg537,00€100mg772,00€1mL*10mM (DMSO)116,00€LOXO-195
CAS :(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.Formule :C20H21FN6ODegré de pureté :97.92%Couleur et forme :SolidMasse moléculaire :380.42PF-06737007
CAS :PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively).Formule :C25H28F4N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.49Altiratinib
CAS :Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formule :C26H21F3N4O4Degré de pureté :98.98% - 99.39%Couleur et forme :SolidMasse moléculaire :510.46
